Search PubMed⌕ Search

Biomedical subjects

M Fukui

Publications and source records attributed to M Fukui.

At least 667 records · Page 37Linked to original sources
PubMed1983

Adenoid cystic carcinoma of lacrimal gland.

Adenoid cystic carcinoma of the lacrimal gland is a relatively rare disease. Only two cases, a man of 61 and a woman of 54 were seen in our clinic from 1962-1981. They presented histopathology of the cribriform pattern characteristic of adenoid cystic carcinoma. The lesion in the male patient belonged to the solid type and was mainly composed of solid nests. It is emphasized that radiotherapy in addition to surgical excision of the tumor is recommended because of its infiltrative nature.

Carcinoma, Adenoid Cystic↗
PubMed1983

[Immunohistochemical studies of hemangioblastoma with glial fibrillary acidic protein].

Sixteen cases of CNS hemangioblastoma were examined for glial fibrillary acidic protein (GFAP) using the immunoperoxidase method. In 13 cases GFAP-positive cells were found in the tumor. In all positive cases reactive gliosis in the form of trapped reactive astrocytes and their cytoplasmic processes penetrated the margin of the tumor. In 4 of the positive cases GFAP-positive cells were present deep in the tumor. Aggregates of GFAP-positive cells and fibrils were especially prominent in a recurrent case. Because hemangioblastomas grow without capsule into the cerebellar tissue, it is considered that reactive astrocytes and their fibrils are easily included and trapped within the tumor. In two cases GFAP-positive plump stromal cells, which were definitely different from the reactive astrocytes, were seen. They were neighbored with the dense gliotic foci or on and around the microcyst wall. This may be interpreted as that the stromal cells have a capacity to incorporate the extracellular GFAP derived from the intratumoral gliotic foci or cysts.

Adolescent↗
PubMed1983

Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors.

By designing optimal administration schedules, it was found that 4-carbamoylimidazolium 5-olate (SM-108) showed an excellent antitumor potency against a number of murine tumors. The optimal administration schedule of SM-108 was an intermittent multiple administration, in which the drug was multiply administered to mice at definite intervals of less than 3 hr for about 1 day on Days 1, 5, and 9 following tumor implantation. Although usual daily administration of SM-108 exhibited poor efficacy, the intermittent multiple administration of SM-108 exhibited potent antitumor activity against a wide variety of tumors, such as Ehrlich carcinoma, P388, 6-mercaptopurine-sensitive and -resistant L1210, Lewis lung carcinoma, Colon 26 adenocarcinoma, and Sarcoma 180. Among them, Ehrlich carcinoma showed the most prominent susceptibility to SM-108. With the intermittent multiple administration of SM-108, complete suppression was obtained in both the ascitic and solid forms of this tumor over a wide dose range. The schedule dependency of the antitumor effect of SM-108 described above was reasonably explained by its in vitro growth-inhibitory effects and pharmacokinetics in the mice.

Animals↗
PubMed1982

Intracranial venous angiomas.

Publications in the scientific literature are controversial in regard to the clinical significance of intracerebral venous angiomas. The present study of 11 patients with venous angiomas underscores the clinical importance of these lesions as potential causes of cerebral hemorrhage and obstructive hydrocephalus. The clinical and radiographic manifestations in 9 of these 11 patients correlated well. In cases of venous angiomas, the venous phase of angiography must be carefully scrutinized, particularly in patients with subarachnoid or intracerebral hemorrhage. Some diagnostic problems related to the angiography of venous angiomas are discussed.

Adolescent↗
PubMed1982

The autonomy of prolactin secretion in patients with prolactin producing tumor.

To examine the responsiveness of prolactin (PRL) secretion in patients with PRL-producing tumor (PRL-noma), TRH (500 micrograms), arginine (0.5 g/kg, b. wt.), and sulpiride (100 mg) were administered to 13 patients with PRL-noma. Seven of these patients responded to TRH or other agents with an increase in their plasma PRL levels of 50% or more above the basal values (categorized as Group I). The remaining six patients, however, showed no response to any of these agents (categorized as Group II). After the administration of L-dopa (500 mg, p.o.), Group I patients showed significantly greater decreases in plasma PRL (-68.9 +/- 6.6%) from the basal value than did Group II (-37.4 +/- 8.6%; p less than 0.02). The mean basal PRL levels were higher in Group II than in Group I, although these differences failed to reach statistical significance. Moreover, there were no differences in age, sellar volume, or the presence of bitemporal hemianopsia between the two groups of patients. It is concluded that there are two patterns of PRL-secretory responses to pharmacological stimuli in patients with PRL-noma. The differences between the two patterns might be characterized by the properties of the lactotroph cells themselves rather than by the relation of these cells to the hypothalamus.

Adult↗
PubMed1982

Lung function in adults with mycoplasmal pneumonia.

We prospectively studied on lung function of 17 patients (7 men and 10 women) of acute Mycoplasma pneumoniae pneumonia. Lung function tests including %VC, FEV1.0%, Peak flow, V75/HT, V25/HT, V50/V25 and MMF were measured during the acute and convalescent stage. The results showed dysfunction of peripheral airway because of reduction in V50/HT, V25/HT and MMF. It was suggested that lung function in patients with Mycoplasma pneumoniae pneumonia was impaired at the high lung volume as well as low lung volume.

Adolescent↗
PubMed1982

Tetrocarcins, new antitumor antibiotics. 3. Antitumor activity of tetrocarcin A.

Tetrocarcin A, isolated from a Micromonospora culture showed activity against experimental i.p. inoculated tumors such as Ehrlich carcinoma, MH134 hepatoma, B16 melanoma. But it was not active against solid tumors such as sarcoma 180 and Ehrlich carcinoma. It was marginally active against the growth of solid Lewis lung carcinoma without prolonging the life span of the tumor-bearing mice. It was active against P388 leukemia (i.v.-i.v. system). It did not show myelosuppression and nephrotoxicity in mice. DNA and protein synthesis of P388 cells in culture were more significantly suppressed than RNA synthesis by tetrocarcin A.

Aminoglycosides↗
PubMed1982

New antitumor imidazole derivative, 5-carbamoyl-1H-imidazol-4-yl piperonylate, as an inhibitor of purine synthesis and its activation by adenine phosphoribosyltransferase.

The mechanism of action of 5-carbamoyl-1H-imidazol-4-yl piperonylate (SL-1250), which has a broad antitumor spectrum, was examined by in vitro cell culture and enzymatic studies. In the serum-containing culture medium, SL-1250 was rapidly deacylated to 4-carbamoylimidazolium 5-olate (SM-108). Thus, SL-1250 might be acting on the cells in the form of SM-108. The growth of L5178Y cells was completely inhibited by 10(-5) M SL-1250. It should be noted that this growth inhibition was significantly reversed in the presence of equimolar concentrations of guanine, guanosine, or guanosine 5'-monophosphate to those of SL-1250. However, hypoxanthine and xanthine were not effective. These effects of purine addition were observed to be quite similar in growth inhibition by SM-108. It was found that inosine 5'-monophosphate dehydrogenase (EC 1.2.1.14; IMP dehydrogenase), a key enzyme of de novo purine synthesis, from Ehrlich carcinoma cells was inhibited by SM-108 only when 5-phospho-alpha-D-ribose 1-diphosphate (PRPP) and MgCl2 coexisted with SM-108. In contrast, a chemically synthetic ribonucleotide of SM-108 inhibited IMP dehydrogenase without PRPP and MgCl2, and the mode of inhibition was competitive with the Ki value of 2 x 10(-8) M. On the other hand, the inhibition of either growth of L5178Y cells or IMP dehydrogenase in the presence of PRPP and MgCl2 by these compounds was reversed by adenine. A nucleotide of SM-108 was chromatographically identified when [14C]SM-108 was incubated in the enzyme solution with PRPP and MgCl2. This conversion by enzyme was also inhibited by adenine. Viewed together, these results strongly suggest that SL-1250 is, after being converted to SM-108, activated to its nucleotide form by adenine phosphoribosyltransferase (EC 2.4.2.7) and that this SM-108 nucleotide blocks de novo synthesis of guanosine 5'-monophosphate by inhibiting IMP dehydrogenase.

Adenine Phosphoribosyltransferase↗